ADIENNE to launch IPO on SIX Swiss Exchange

Please login or
register
12.09.2016
Schweizer Börse

ADIENNE Pharma & Biotech SA announces today its intention to proceed with an initial public offering of ordinary shares and seek a listing of its shares on the SIX Swiss Stock Exchange. The group aims to develop a range of product candidates for orphan diseases.

ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio consisting of an orphan-designated marketed medicinal product and clinical and preclinical product candidates focusing on critical conditions and high unmet medical needs. The Group aims to develop a range of product candidates for orphan diseases, for which existing treatment options are limited, the patient population is small and the clinical need for therapies is high.

The Group is focused on orphan drug development for the treatment of various hematological and immunological diseases, in which the Group has high expertise and proven in-house capabilities from discovery to commercialization. In addition, the Group has its own Good Manufacturing Practice ("GMP")-approved manufacturing facility, which is authorized for the production of biotechnological sterile products for clinical trials and commercial use

60 employees
Dr. Antonio Francesco Di Naro, Chairman and President, started in 2004 to build the Group, which currently has 60 employees. The Company’s headquarters are based in Lugano (Switzerland), its manufacturing site is based in Caponago (Italy) and a subsidiary is located in Barcelona (Spain).

ADIENNE’s proprietary lead candidate Begelomab is currently running a Phase II/III FDAand EMA registrative study for steroid-resistant acute Graft-versus-Host Disease ("sraGvHD"), for which it has received orphan drug designation (ODD) in U.S., EU and Switzerland. Begelomab is an immunomodulatory monoclonal Antibody ("mAb") targeting the CD26 receptor on a subset of T cells associated with autoimmune conditions.

ADIENNE is the exclusive marketing authorization holder for TEPADINA in EU, Russia, Israel, Hong Kong and Switzerland, as well as ODDs from FDA, EMA and Swissmedic. TEPADINA is currently marketed in 42 countries worldwide, and is indicated, in combination with other chemotherapy medicinal products, with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients and when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients. With the successful marketing of TEPADINA, ADIENNE has an existing international commercialization footprint which it can draw upon when commercializing its other product candidates.

ADIENNE is also developing three preclinical product candidates: ADN-LYS, ADN-MCL and MUBODINA for Gaucher’s Disease, Mantle Cell Lymphoma and typical Haemolytic Uremic Syndrome, respectively.

Dr. Antonio Francesco Di Naro said: “I am very much looking forward to seeking a listing of ADIENNE on the SIX Swiss Exchange which will clearly enlarge the international footprint of the company. The proceeds from the planned IPO would further support the ongoing Phase II/III FDA and EMA registrative clinical trial of Begelomab for steroidresistant acute Graft-versus-Host Disease, the scale up the Group's manufacturing, our commercialization capabilities ahead of the launch of Begelomab and the other trials of our clinical and preclinical development programs. I plan to retain a clear majority stake in the Company and will remain fully committed to develop ADIENNE into the next phase of its corporate development.”

(Press release)

Picture: SIX

0Comments

More news about

ADIENNE

rss